Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The decrease of particle-induced osteolysis after a single dose of bisphosphonate.

Marius von Knoch1, Christian Wedemeyer, Andreas Pingsmann

  • 1Department of Orthopaedics, University of Duisburg-Essen, Pattbergstrasse 1-3, 45239 Essen, Germany. mariusvonknoch@yahoo.com

Biomaterials
|December 4, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-Step Extrusion Printing of Microgrooved Annulus Fibrosus Scaffolds via Patterned Nozzles.

Journal of functional biomaterials·2026
Same author

Influence of elastic stable intramedullary nailing on fracture reduction of paediatric diaphyseal forearm fractures.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2026
Same author

[Identification of joint-specific risk factors for risk adjustment in total knee arthroplasty-A modified Delphi process].

Orthopadie (Heidelberg, Germany)·2026
Same author

Ethical considerations in lethal sampling of aquatic vertebrate hosts in parasitological studies.

Trends in parasitology·2025
Same author

Bite injuries at a level 1 trauma center in Germany.

Trauma surgery & acute care open·2025
Same author

Indications for the addition of a patellofemoral joint arthroplasty following a previous unicondylar knee arthroplasty- a literature review and Delphi consensus.

Archives of orthopaedic and trauma surgery·2025

A single dose of zoledronic acid (ZA), a potent bisphosphonate, significantly reduced bone loss from particle-induced osteolysis in mice. This finding offers a promising new treatment for implant failure, potentially reducing side effects compared to daily bisphosphonate use.

Area of Science:

  • Orthopedics
  • Biomaterials Science
  • Pharmacology

Background:

  • Implant failure in joint replacements is often caused by aseptic loosening, primarily due to particle-induced osteolysis.
  • Bisphosphonates are effective in treating particle-induced osteolysis, but typically require daily administration.
  • Investigating potent, third-generation bisphosphonates for single-dose efficacy is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the effect of a single subcutaneous dose of a third-generation bisphosphonate, zoledronic acid (ZA), on particle-induced osteolysis.
  • To compare the efficacy of ZA administered immediately after surgery versus four days postoperatively.
  • To assess the potential of single-dose bisphosphonate therapy to mitigate implant failure.

Main Methods:

Related Experiment Videos

  • The study utilized the murine calvaria osteolysis model in C57BL/J6 mice.
  • Bone resorption was quantified using Giemsa staining to measure resorption within the midline suture.
  • Mice were divided into groups receiving particle implantation alone or with a single dose of zoledronic acid (ZA) at different time points.

Main Results:

  • Particle implantation led to significant bone resorption (0.26+/-0.09 mm²).
  • A single dose of ZA, administered either immediately after surgery or four days postoperatively, markedly decreased bone resorption (0.14+/-0.05 mm² and 0.15+/-0.05 mm², respectively; p < 0.007).
  • These results demonstrate a significant reduction in bone resorption with single-dose ZA treatment.

Conclusions:

  • A single subcutaneous dose of a potent third-generation bisphosphonate effectively reduces particle-induced bone resorption.
  • Single-dose bisphosphonate treatment represents a promising strategy for managing particle-induced osteolysis and may reduce treatment-related side effects.
  • This approach holds significant potential for improving the longevity of joint replacement implants.